Cluster Headache Syndrome - Pipeline Review, Q4 2010

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Report Coverage
3 Introduction
3.1 About Cluster Headache Syndrome
3.2 An Overview of Cluster Headache Syndrome Therapeutics
4 Cluster Headache Syndrome Therapeutics Development
4.1 An Overview of Pipeline Products for Cluster Headache Syndrome
4.2 Cluster Headache Syndrome Therapeutics under Development by Companies
4.3 Cluster Headache Syndrome Therapeutics under Investigation by Universities/Institutes
4.4 Late Clinical Stage Products
4.4.1 Comparative Analysis
4.4.2 Late Clinical Stage Products - Companies
4.4.3 Late Clinical Stage Products - Universities/Institutes
4.5 Mid Clinical Stage Products
4.5.1 Comparative Analysis
4.5.2 Mid Clinical Stage Products - Companies
4.5.3 Mid Clinical Stage Products - Universities/Institutes
4.6 Early Clinical Stage Products
4.6.1 Comparative Analysis
4.6.2 Early Clinical Stage Products - Companies
4.6.3 Early Clinical Stage Products - Universities/Institutes
4.7 Pre-clinical and Discovery Stage Products
4.7.1 Comparative Analysis
4.7.2 Pre-clinical and Discovery Stage Products - Companies
5 Companies Involved in Cluster Headache Syndrome Therapeutics Development
6 Universities/Institutes Involved in Cluster Headache Syndrome Therapeutics Development
7 Cluster Headache Syndrome Therapeutics Assessment
7.1 Assessment by Monotherapy Products
7.2 Assessment by Combined Therapeutics
7.3 Assessment by Therapeutic Class
7.4 Assessment by Route of Administration
7.5 Assessment by Molecule Type
7.5.1 Assessment by Biologics/Non-Biologics under Development
8 Late Stage Drug Profiles – Company
8.1 Drug 1 Profile
8.1.1 Product Description
8.1.2 Mechanism of Action
8.1.3 R&D Progress
9 Late Stage Drug Profiles – Universities/Institutes
9.1 Drug 1 Profile
9.1.1 Product Description
9.1.2 Mechanism of Action
9.1.3 R&D Progress
10 Cluster Headache Syndrome Therapeutics - Discontinued Company Products
11 Cluster Headache Syndrome Therapeutics – Featured News
12 Appendix
12.1 Research Methodology
12.2 Secondary Research
12.3 Consulting
12.4 Contact Us
12.5 Disclaimer


1.1 List of Tables

Table 1: Number of Products under Development, 2010
Table 2: Cluster Headache Syndrome Products under Development – Comparative Analysis, 2010
Table 3: Number of Products under Development by Companies, 2010
Table 4: Number of Products under Investigation by Universities/Institutes, 2010
Table 5: Comparative Analysis by Late Clinical Stage Development, 2010
Table 6: Late Clinical Stage Products – Companies, 2010
Table 7: Late Clinical Stage Products - Universities/Institutes, 2010
Table 8: Comparative Analysis by Mid Clinical Stage Development, 2010
Table 9: Mid Clinical Stage Products - Companies, 2010
Table 10: Mid Clinical Stage Products - Universities/Institutes, 2010
Table 11: Comparative Analysis by Early Clinical Stage Development, 2010
Table 12: Early Clinical Stage Products - Companies, 2010
Table 13: Early Clinical Stage Products - Universities/Institutes, 2010
Table 14: Comparative Analysis by Pre-clinical and Discovery Stage Development, 2010
Table 15: Pre-clinical and Discovery Stage Products - Companies, 2010
Table 16: Companies Involved in Cluster Headache Syndrome Therapeutics Development - Company 1
Table 17: Products under Investigation by Universities/Institutes, 2010
Table 19: Assessment by Monotherapy Products, 2010
Table 20: Assessment by Combined Therapeutics, 2010
Table 21: Assessment by Therapeutic Class, 2010
Table 22: Assessment by Route of Administration, 2010
Table 23: Assessment by Molecule Type, 2010
Table 24: Assessment by Biologics/Non-Biologics, 2010
Table 25: Discontinued Company Products


1.2 List of Figures

Figure 1: Number of Products under Development, 2010
Figure 2: Cluster Headache Syndrome Products under Development – Comparative Analysis, 2010
Figure 3: Products under Development by Companies, 2010
Figure 4: Products under Investigation by Universities/Institutes, 2010
Figure 5: Late Clinical Stage Products, 2010
Figure 6: Mid Clinical Stage Products, 2010
Figure 7: Early Clinical Stage Products, 2010
Figure 8: Pre-clinical and Discovery Stage Products, 2010
Figure 9: Assessment by Monotherapy Products, 2010
Figure 10: Assessment by Combined Therapeutics, 2010
Figure 11: Comparative Analysis - Monotherapy and Combined Therapeutics, 2010
Figure 12: Assessment by Therapeutic Class, 2010
Figure 13: Assessment by Stage and Therapeutic Class, 2010
Figure 14: Assessment by Route of Administration, 2010
Figure 15: Assessment by Stage and Route of Administration, 2010
Figure 16: Assessment by Molecule Type, 2010
Figure 17: Assessment by Stage and Molecule Type, 2010
Figure 18: Assessment by Biologics/Non-Biologics, 2010